Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease
<p dir="ltr">Sickle cell disease (SCD) is a heterogeneous group of inherited disorders characterized by the production of sickle hemoglobin which is less soluble than an adult or fetal hemoglobin. Voxelotor is a hemoglobin S polymerization inhibitor that has been approved for sickle...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513547863588864 |
|---|---|
| author | Awni Alshurafa (15468195) |
| author2 | Mohamed A. Yassin (8361183) |
| author2_role | author |
| author_facet | Awni Alshurafa (15468195) Mohamed A. Yassin (8361183) |
| author_role | author |
| dc.creator.none.fl_str_mv | Awni Alshurafa (15468195) Mohamed A. Yassin (8361183) |
| dc.date.none.fl_str_mv | 2022-09-15T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3389/fmed.2022.931924 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Case_report_Safety_and_efficacy_of_voxelotor_in_a_patient_with_sickle_cell_disease_and_stage_IV_chronic_kidney_disease/29098466 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences sickle cell disease voxelotor hemolysis chronic kidney disease vaso-occlusive crisis (VOC) |
| dc.title.none.fl_str_mv | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Sickle cell disease (SCD) is a heterogeneous group of inherited disorders characterized by the production of sickle hemoglobin which is less soluble than an adult or fetal hemoglobin. Voxelotor is a hemoglobin S polymerization inhibitor that has been approved for sickle cell disease treatment in the adult and adolescent populations. It acts as a hemoglobin modulator by increasing its affinity to oxygen which prevents red blood cells from sickling. Chronic kidney disease is a common but under-reported complication of SCD and it is a leading cause of morbidity and mortality. The data about the safety and efficacy of voxelotor use in chronic kidney disease is limited. Herein we report a 49-year-old man, with sickle cell disease and stage IV chronic kidney disease, who was managed successfully with voxelotor and resulted in decreasing transfusion requirement and vaso-occlusive painful crisis without affecting kidney function.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fmed.2022.931924" target="_blank">https://dx.doi.org/10.3389/fmed.2022.931924</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_532b9498feb847909e3554cbc700574b |
| identifier_str_mv | 10.3389/fmed.2022.931924 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29098466 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney diseaseAwni Alshurafa (15468195)Mohamed A. Yassin (8361183)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencessickle cell diseasevoxelotorhemolysischronic kidney diseasevaso-occlusive crisis (VOC)<p dir="ltr">Sickle cell disease (SCD) is a heterogeneous group of inherited disorders characterized by the production of sickle hemoglobin which is less soluble than an adult or fetal hemoglobin. Voxelotor is a hemoglobin S polymerization inhibitor that has been approved for sickle cell disease treatment in the adult and adolescent populations. It acts as a hemoglobin modulator by increasing its affinity to oxygen which prevents red blood cells from sickling. Chronic kidney disease is a common but under-reported complication of SCD and it is a leading cause of morbidity and mortality. The data about the safety and efficacy of voxelotor use in chronic kidney disease is limited. Herein we report a 49-year-old man, with sickle cell disease and stage IV chronic kidney disease, who was managed successfully with voxelotor and resulted in decreasing transfusion requirement and vaso-occlusive painful crisis without affecting kidney function.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fmed.2022.931924" target="_blank">https://dx.doi.org/10.3389/fmed.2022.931924</a></p>2022-09-15T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3389/fmed.2022.931924https://figshare.com/articles/journal_contribution/Case_report_Safety_and_efficacy_of_voxelotor_in_a_patient_with_sickle_cell_disease_and_stage_IV_chronic_kidney_disease/29098466CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/290984662022-09-15T09:00:00Z |
| spellingShingle | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease Awni Alshurafa (15468195) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences sickle cell disease voxelotor hemolysis chronic kidney disease vaso-occlusive crisis (VOC) |
| status_str | publishedVersion |
| title | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| title_full | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| title_fullStr | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| title_full_unstemmed | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| title_short | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| title_sort | Case report: Safety and efficacy of voxelotor in a patient with sickle cell disease and stage IV chronic kidney disease |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences sickle cell disease voxelotor hemolysis chronic kidney disease vaso-occlusive crisis (VOC) |